Evidence map›Paper›PMID 41736104›Full record

ArticleJournal of translational medicine2026

A pathology-to-single-cell framework links SPP1

Ruixiang Li, Yuheng Gu, Shi Huang, Shiya Zeng, Xuanchen Zhou, Weiqi Luo, Zhuo Wen, Wenjing Chen, Cheng Chen, Lantian Cui and 2 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ruixiang Li *Clinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Yuheng Gu *Clinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Shi Huang *Clinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Shiya Zeng *Clinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Xuanchen ZhouClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Weiqi LuoClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Zhuo WenClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Wenjing ChenClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Cheng ChenClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Lantian CuiClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Hongyu DuanSchool of Nursing, Chongqing College of Humanities, Science & Technology, Chongqing, 401524, China.
Mengfan ZhaoDepartment of Breast Surgery, The Affliated Hospital, Southwest Medical University, Luzhou, 646000, China. 512640872@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeutrophil extracellular traps (NETs) facilitate hepatocellular carcinoma (HCC) progression, but the upstream cellular organizers and the histopathological correlates of NETosis-prone niches remain poorly defined. We aimed to build a pathology-to-single-cell framework to (i) quantify NETs-associated risk from routine whole-slide images (WSI) and (ii) nominate candidate organizer cells and mechanisms, focusing on SPP1+ M2 macrophages.

methodsWe integrated WSI, bulk transcriptomics, single-cell RNA-seq, spatial transcriptomics, and germline association data. NETs activity was quantified using gene-set scoring and aligned with WSI-derived morphology features (e.g. texture, stromal boundary disruption, and tumor–stroma interface complexity) to train and validate a prognostic model using regularized feature selection and survival machine learning. A 26,928-cell single-cell atlas was constructed to annotate macrophage states and neutrophil subsets, followed by trajectory inference to model macrophage polarization dynamics. Cell–cell communication was evaluated by ligand–receptor co-expression networks, and pathway/metabolic programs were inferred using multi-method enrichment and flux estimation. Spatial co-localization and neighborhood effects were assessed by deconvolution and spatial interaction modeling. Finally, network-based target prioritization was performed to highlight druggable nodes and candidate intervention pathways.

resultsThe WSI-derived NETs risk score stratified overall survival in training and validation cohorts (HR ≈ 8.48 and ≈6.44; AUC > 0.78). Multi-omics integration prioritized SPP1 as a central hub. SPP1+ M2 macrophages and NETs+ neutrophils preferentially localized at the tumor–stroma interface, where inferred communication converged on OPN(SPP1)–CD44/integrins and ICAM1–β2-integrin axes with downstream FAK–PI3K–Akt and NF-κB/MAPK signaling. Metabolic inference suggested a shared hypoxia/glycolysis–lactate–glutathione/antioxidant program in SPP1+ M2 macrophages mirrored by NETs+ neutrophils, consistent with a NETosis-permissive niche. Germline mapping indicated an antagonistic association pattern for the SPP1+ M2 program. Network prioritization highlighted SRC, AKT1, and CEBPB and pathways including ECM–receptor interaction, FAK/PI3K–Akt, MAPK, and TNF/IL-17.

conclusionsOur framework links routine pathology morphology to NETs activity and nominates SPP1+ M2 macrophages as candidate organizers of NETosis-prone high-risk niches in HCC. Importantly, the proposed macrophage–NETs axis is supported by convergent multi-omics/spatial evidence but remains primarily associative and inference-based, not definitive causation. Future work should include functional validation (e.g. macrophage–neutrophil co-culture NETosis assays, SPP1/CD44/integrin or ICAM1–ITGB2 perturbation, and in vivo depletion/blockade studies), prospective multi-center evaluation of the WSI risk score, and testing whether this axis generalizes beyond HCC or is liver-specific. These results provide a quantitative pathology-based risk stratification approach and a set of mechanistically plausible, targetable signaling–metabolic nodes for therapeutic exploration.

Indexed as

Carcinoma, HepatocellularExtracellular TrapsLiver NeoplasmsMacrophagesOsteopontinSingle-Cell AnalysisGene Expression Regulation, NeoplasticHumansRisk FactorsTumor MicroenvironmentOsteopontinSPP1 protein, humanHepatocellular carcinomaNETsPathology-omicsSPP1+ M2 macrophages

Identifiers

PMID41736104
PMCPMC13040768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.